Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000178635 | SCV000230751 | likely benign | not specified | 2015-02-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000870530 | SCV001012034 | likely benign | not provided | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000870530 | SCV002586570 | uncertain significance | not provided | 2024-03-05 | criteria provided, single submitter | clinical testing | Observed with additional FRAS1 variants (phase unknown) in a patient with focal segmental glomerulosclerosis in published literature (PMID: 31308072); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 35368817, 31308072) |
Ambry Genetics | RCV002516778 | SCV003569074 | uncertain significance | Inborn genetic diseases | 2024-05-15 | criteria provided, single submitter | clinical testing | The c.6584A>G (p.E2195G) alteration is located in exon 47 (coding exon 47) of the FRAS1 gene. This alteration results from a A to G substitution at nucleotide position 6584, causing the glutamic acid (E) at amino acid position 2195 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV000870530 | SCV004699716 | likely benign | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | FRAS1: BP4, BS2 |
Prevention |
RCV003927667 | SCV004738410 | likely benign | FRAS1-related disorder | 2019-03-27 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |